

Nasal Corticosteroids

Key Questions and Inclusion Criteria

Key Questions

1. For adults and children with seasonal or perennial (allergic and non-allergic) rhinitis, do nasal corticosteroids differ in effectiveness?
2. For adults and children with seasonal or perennial (allergic and non-allergic) rhinitis, do nasal corticosteroids differ in safety or adverse events?
3. Are there subgroups of patients based on demographics (age, racial groups, gender), other medications, or co-morbidities, or in pregnancy and lactation for which one nasal corticosteroid is more effective or associated with fewer adverse events?

Inclusion Criteria

Populations

Adult patients and children (under age 18) in outpatient settings with the following diagnosis:

- Seasonal or perennial allergic or non-allergic rhinitis

Interventions

Generic Name	Trade Name	Forms	Manufacturer
Mometasone	Nasonex	Nasal spray	Schering
Fluticasone	Flonase	Nasal spray	GlaxoSmithKline
Budesonide	Rhinocort, Rhinocort Aqua	Nasal spray	AstraZeneca
Triamcinolone	Nasacort, Nasacort AQ	Nasal spray	Sanofi-Aventis
Beclomethasone	Beconase, Beconase AQ	Nasal spray	GlaxoSmithKline
Beclomethasone	Vancenase, Vancenase AQ	Nasal spray	Schering
Flunisolide	Nasalide, Nasarel	Nasal spray	Ivax

Effectiveness Outcomes

Population	Outcomes
Seasonal or perennial allergic or non-allergic rhinitis	<ol style="list-style-type: none"> 1. Symptomatic relief 2. Onset of action

Safety Outcomes

- Overall adverse effect reports
- Withdrawals due to adverse effects
- Serious adverse events reported
- Specific adverse events (localized infection of nasal mucosa, hypersensitivity, hypercorticism, HPA suppression, growth suppression in pediatric population, headache, throat soreness, dry mouth, nasal irritation)

Study Designs

1. For efficacy, controlled clinical trials and good-quality systematic reviews
2. For safety, controlled clinical trials and good-quality systematic reviews and observational studies.